Diagnostics

Xenomonitoring of black flies to confirm serologic threshold for onchocerciasis elimination mapping

To determine the appropriate serologic threshold(s) to be used to initiate MDA for onchocerciasis

Countries: Malawi
Diseases: Onchocerciasis

Does infection data add evidence to the understanding of trachoma prevalence in low endemic areas?

  1. To evaluate strategies for the elimination of trachoma by evaluating potential makers that show interruption of transmission of C. trachomatis
  2. To determine the prevalence of ocular chlamydial infection among children aged 1 – 9 years old in Mpwapwa and Kalambo District, Tanzania
  3. To determine the associated risk factors of ocular Chlamydia infection among children aged 1 – 9 years old in Mpwapwa and Kalambo District, Tanzania
  4. To determine the usability of antibody test to detect Chlamydia antigen pgp3 using lateral flow assay
  5. To examine the longevity of the antibody response to trachoma antigens in a high and low-prevalence setting
Countries: Tanzania
Diseases: Trachoma

TAS 3 positive case follow-up

Is there still LF transmission after successful TAS 3?

Countries: Nepal

Post-validation survey for the elimination of blinding trachoma to evaluate the effectiveness of a serological surveillance strategy in two provinces of Morocco

Conduct district-wide field trials of the Pgp3 lateral flow assay to measure the seroprevalence of antibodies against the Chlamydia trachomatis antigen Pgp3 in low-prevalence settings.

Countries: Morocco
Diseases: Trachoma

Ov16 and Wb123 ELISA for onchocerciasis elimination mapping (OEM) Ethiopia

Would the same programmatic decisions for Oncho Elimination Mapping be made based off of the Ov16 RDT results as compared to the Ov16 SD ELISA results in 7 woredas included in OEM in Ethiopia?

Countries: Ethiopia

Evaluation of elimination of onchocerciasis in Malawi using the OV-16 serologic test

Evaluate the current status of transmission of onchocerciasis in a hyperendemic area treated for many years and in a hypoendemic area treated for lymphatic filariasis for 5 years using the Ov16 ELISA and supplemented by entomology results from a previous study

Countries: Malawi
Diseases: Onchocerciasis

Field friendly biometry to ease cohort studies in resource-limited settings: application to the Test and Treat for onchocerciasis project in Central Cameroon

Can a biometric recognition system, in the context of “Test and Treat”, facilitate individual follow-up by linking participant data at different time-points?

Countries: Cameroon
Diseases: Loiasis | Onchocerciasis

Investigation of communities at increased risk of trachoma recrudescence & a model post-elimination surveillance strategy

Primary research question

Is there evidence of on-going or recent ocular Ct transmission in communities of northern Ghana felt to be at increased risk of recrudescence, at least two years since they were identified with Ct infection and or high anti-Pgp3 seroprevalence during pre-validation trachoma surveillance surveys?

Secondary research questions

What is the geographical extent of the boundaries of any persistent Ct infection and on-going transmission in the post-elimination setting?

What is the community-level (anti-Pgp3) prevalence of seropositivity for the multiplex bead array (MBA) (and possibly ELISA) as compared to the lateral flow assay (LFA)?

Countries: Ghana
Diseases: Trachoma

Ov16 AP ELISA comparison in Cameroon

How does the performance of the AP ELISA compare to the Ov16 SD ELISA, when conducted in a country lab?

Countries: Cameroon
Diseases: Onchocerciasis

Understanding areas of increased trachoma risk (hotspots) through the implementation of a post validation trachoma surveillance strategy

To determine if there is evidence of on-going or recent transmission in the “hotspot” communities of increased risk two years after they were identified during the pre-validation surveys (clinical, antibody and infection data).

Countries: Ghana
Diseases: Trachoma

Pages